These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9250792)

  • 1. 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders.
    Kong LR; Samuelson E; Rosen ST; Roenigk HH; Tallman MS; Rademaker AW; Kuzel TM
    Leuk Lymphoma; 1997 Jun; 26(1-2):89-97. PubMed ID: 9250792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma.
    Kuzel TM; Hurria A; Samuelson E; Tallman MS; Roenigk HH; Rademaker AW; Rosen ST
    Blood; 1996 Feb; 87(3):906-11. PubMed ID: 8562961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
    Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS
    Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders.
    Rondelli D; Lauria F; Zinzani PL; Raspadori D; Ventura MA; Galieni P; Birtolo S; Forconi F; Algeri R; Tura S
    Eur J Haematol; 1997 Jan; 58(1):46-50. PubMed ID: 9020373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma.
    Saven A; Carrera CJ; Carson DA; Beutler E; Piro LD
    Blood; 1992 Aug; 80(3):587-92. PubMed ID: 1353380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders.
    O'Brien S; Kurzrock R; Duvic M; Kantarjian H; Stass S; Robertson LE; Estey E; Pierce S; Keating MJ
    Blood; 1994 Aug; 84(3):733-8. PubMed ID: 7913841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine.
    Bouwhuis SA; el-Azhary RA; McEvoy MT; Gibson LE; Habermann TM; Witzig TE; Pittelkow MR
    Int J Dermatol; 2002 Jun; 41(6):352-6. PubMed ID: 12100691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.
    Robak T; Smolewski P; Urbanska-Rys H; Gora-Tybor J; Blonski JZ; Kasznicki M
    Leuk Lymphoma; 2004 May; 45(5):937-44. PubMed ID: 15291352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
    Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
    J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
    Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
    J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study.
    Jäger G; Neumeister P; Brezinschek R; Hinterleitner T; Fiebiger W; Penz M; Neumann HJ; Mlineritsch B; DeSantis M; Quehenberger F; Chott A; Beham-Schmid C; Höfler G; Linkesch W; Raderer M
    J Clin Oncol; 2002 Sep; 20(18):3872-7. PubMed ID: 12228207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia.
    Saven A; Lee T; Schlutz M; Jacobs A; Ellison D; Longmire R; Piro L
    J Clin Oncol; 1997 Jan; 15(1):37-43. PubMed ID: 8996122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.
    Róbak T; Gora-Tybor J; Krykowski E; Walewski JA; Borawska A; Pluźańska A; Potemski P; Hellmann A; Zaucha JM; Konopka L; Ceglarek B; Durźyński T; Sikorska A; Michalak K; Urasiński J; Opalińska J; Dmoszyńska A; Adamczyk-Cioch MB; Kuratowska Z; Dwilewicz-Trojaczek J; Boguradzki P; Deren M; Maj S; Grieb P
    Leuk Lymphoma; 1997 Jun; 26(1-2):99-105. PubMed ID: 9250793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
    Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
    Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
    Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
    Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
    Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
    de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
    Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.
    Saven A; Lemon RH; Kosty M; Beutler E; Piro LD
    J Clin Oncol; 1995 Mar; 13(3):570-4. PubMed ID: 7884417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders.
    Saven A; Piro LD
    Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S93-101. PubMed ID: 9137962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.